-
Mashup Score: 1Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study - 5 month(s) ago
This study suggests that emicizumab prophylaxis prevents bleeding in patients with acquired haemophilia A and that immunosuppressive therapy can be deferred while patients are receiving this treatment. The low number of thromboembolic events, severe infections, and fatalities observed in this study are promising.
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Acquired haemophilia A is a rare disorder that affects older adults with no previous bleeding history who develop life-threatening bleeding, accompanied by a prolonged activated partial thromboplastin time that fails to correct in a 1:1 mix and caused by a specific autoantibody to factor VIII.1,2 The aim of acquired haemophilia treatment is two-fold: to stop the bleeding, and to eradicate the inhibitor. To date, standard treatment includes haemostatic bypassing agents to prevent bleeding and immunosuppressives to eradicate the inhibitor, which is 90% effective.
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A - 7 month(s) ago
Introduction In recent years, there has been increased focus on individualizing treatment for persons with hemophilia including pharmacokinetic-guided (PK) dosing. Aims In this retrospective study…
Source: onlinelibrary.wiley.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Realising the Promise of Gene Therapy for Haemophilia: Current Status and Future Innovations - 11 month(s) ago
Gene therapy for haemophilia A and B was discussed during several sessions at the 64th American Society of Hematology (ASH) Annual Meeting…
Source: European Medical JournalCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial - 12 month(s) ago
In participants with haemophilia A or B without inhibitors, fitusiran prophylaxis resulted in significant reductions in annualised bleeding rate compared with on-demand clotting factor concentrates and no bleeding events in approximately half of participants. Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Alok Srivastava on fitusiran for patients with haemophilia A and B - In conversation with... - 12 month(s) ago
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.Read the two trials:Efficacy and safety of fitusira…
Source: BuzzsproutCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Alok Srivastava on fitusiran for patients with haemophilia A and B - In conversation with... - 1 year(s) ago
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.Read the two trials:Efficacy and safety of fitusira…
Source: BuzzsproutCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In participants with haemophilia A or B without inhibitors, fitusiran prophylaxis resulted in significant reductions in annualised bleeding rate compared with on-demand clotting factor concentrates and no bleeding events in approximately half of participants. Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in haemophilia care in the Philippines - 1 year(s) ago
Haemophilia is a bleeding disorder that predisposes individuals affected, primarily males, to bleeding diathesis and spontaneous bleeding into joints, soft tissues, and muscles in varying severities. In the Philippines, there are approximately 1604 patients diagnosed with haemophilia according to the World Federation of Hemophilia 2020 report. However, the real prevalence of disease might be at…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission - 1 year(s) ago
HEMGENIX® underscores CSL’s promise to deliver life-changing innovations that have the potential to help patients lead full lives MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ — Global…
Source: Global Newsroom | CSLCategories: Hem/Oncs, Latest HeadlinesTweet
NEW: results from the GTH-AHA-EMI trial show that emicizumab prophylaxis protects patients with acquired #haemophilia A from bleeding and allows deferral of immunosuppression during the first 12 weeks after diagnosis #hemophilia #bleedingdisorders https://t.co/Cc07bH1KJ6 https://t.co/RqMjNMquzi